R^3 is selected from the group consisting of hydrogen, halogen, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, $(C_1$-$C_4)$alkoxy, —$B(OH)_2$, $(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$cycloalkyl$(C_1$-$C_4)$alkyl-, $(C_6$-$C_{10})$bicycloalkyl, heterocycloalkyl, heterocycloalkyl$(C_1$-$C_4)$alkyl-, phenyl, phenyl$(C_1$-$C_2)$alkyl, heteroaryl, heteroaryl$(C_1$-$C_2)$alkyl, cyano, —$C(O)R^a$, —CO_2R^a, —$C(O)NR^aR^b$, —$C(O)NR^aNR^aR^b$, —$S(O)R^a$, —SO_2R^a, —$SO_2NR^aR^b$, nitro, —NR^aR^b, $R^aR^bN(C_1$-$C_4)$alkyl-, —$NR^aC(O)R^b$, —$NR^aC(O)NR^aR^b$, —$NR^aC(O)OR^a$, —$NR^aSO_2R^b$, —$NR^aSO_2NR^aR^b$, —$NR^aNR^aR^b$, —$NR^aNR^aC(O)R^b$, —$NR^aNR^aC(O)NR^aR^b$, —$NR^aNR^aC(O)OR^a$, —OR^a, $R^aO(C_1$-$C_4)$alkyl-, $R^aO(C_3$-$C_6)$alkynyl-, —$OC(O)R^a$, and —$OC(O)NR^aR^b$, wherein each cycloalkyl, bicycloalkyl, heterocycloalkyl, phenyl, or heteroaryl group is optionally substituted 1, 2, or 3 times, independently, by R^c—$(C_1$-$C_6)$alkyl-O—, R^c—$(C_1$-$C_6)$alkyl-S—, R^c—$(C_1$-$C_6)$alkyl-, $(C_1$-$C_4)$alkyl-heterocycloalkyl-, halogen, $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cycloalkyl, halo$(C_1$-$C_6)$alkyl, cyano, —$C(O)R^a$, —CO_2R^a, —$C(O)NR^aR^b$, —$S(O)R^a$, —SO_2R^a, —$SO_2NR^aR^b$, nitro, —NR^aR^b, —$NR^aC(O)R^b$, —$NR^aC(O)NR^aR^b$, —$NR^aC(O)OR^a$, —$NR^aSO_2R^b$, —$NR^aSO_2NR^aR^b$, —OR^a, —$OC(O)R^a$, —$OC(O)NR^aR^b$, heterocycloalkyl, phenyl, heteroaryl, phenyl$(C_1$-$C_2)$alkyl, or heteroaryl$(C_1$-$C_2)$alkyl;

R^4 is hydrogen, $(C_1$-$C_4)$alkyl, or hydroxy$(C_2$-$C_4)$alkyl-;

each R^c is independently —$S(O)R^a$, —SO_2R^a, —NR^aR^b, —$NR^aC(O)OR^a$, —$NR^aSO_2R^b$, or —CO_2R^a; and

R^a and R^b are each independently hydrogen, $(C_1$-$C_4)$alkyl, hydroxy$(C_1$-$C_4)$alkyl-, $(C_1$-$C_4)$alkoxy$(C_1$-$C_4)$alkyl-, $(C_3$-$C_6)$cycloalkyl, $(C_6$-$C_{10})$bicycloalkyl, heterocycloalkyl, phenyl, phenyl$(C_1$-$C_2)$alkyl-, heteroaryl$(C_1$-$C_4)$alkyl-, or heteroaryl, wherein any said cycloalkyl, bicycloalkyl, heterocycloalkyl, phenyl, or heteroaryl group is optionally substituted 1, 2, or 3 times, independently, by halogen, hydroxyl, $(C_1$-$C_4)$alkoxy, amino, —$NH(C_1$-$C_4)$alkyl, —$N((C_1$-$C_4)$alkyl$)_2$, —NH(halo$(C_1$-$C_4)$alkyl), —N(halo$(C_1$-$C_4)$alkyl$)_2$, —N($(C_1$-$C_4)$alkyl)(halo$(C_1$-$C_4)$alkyl), $(C_1$-$C_4)$alkyl, halo$(C_1$-$C_4)$alkyl, hydroxy$(C_1$-$C_4)$alkyl-, $(C_1$-$C_4)$alkoxy$(C_1$-$C_4)$alkyl-, $(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$cycloalkyl$(C_1$-$C_4)$alkyl-, heterocycloalkyl optionally substituted by one or two halogens, heterocycloalkyl$(C_1$-$C_4)$alkyl-, heteroaryl optionally substituted by $(C_1$-$C_4)$alkyl, heteroaryl$(C_1$-$C_4)$alkyl- optionally substituted by $(C_1$-$C_4)$alkyl, $(C_1$-$C_4)$alkoxycarbonyl$(C_1$-$C_4)$alkyl-, —CO_2H, —$CO_2(C_1$-$C_4)$alkyl, —$CONH_2$, —$CONH(C_1$-$C_4)$alkyl, —$CON((C_1$-$C_4)$alkyl$)_2$, —$SO_2(C_1$-$C_4)$alkyl, —SO_2NH_2, —$SO_2NH(C_1$-$C_4)$alkyl, or —$SO_2N((C_1$-$C_4)$alkyl$)_2$;

or R^a and R^b taken together with the nitrogen to which they are attached represent a 5- or 6-membered saturated or unsaturated ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted 1, 2, or 3 times, independently, by $(C_1$-$C_4)$alkyl, halo$(C_1$-$C_4)$alkyl, amino, —$NH(C_1$-$C_4)$alkyl, —$N((C_1$-$C_4)$alkyl$)_2$, hydroxyl, oxo, $(C_1$-$C_4)$alkoxy, or $(C_1$-$C_4)$alkoxy$(C_1$-$C_4)$alkyl-, wherein said ring is optionally fused to a $(C_3$-$C_6)$cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl ring;

or R^a and R^b taken together with the nitrogen to which they are attached represent a 6- to 10-membered bridged bicyclic ring system optionally fused to a $(C_3$-$C_6)$cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl ring;

or a pharmaceutically acceptable salt thereof.

2. The compound or pharmaceutically acceptable salt according to claim **1**, wherein X is CH.

3. The compound or pharmaceutically acceptable salt according to claim **1**, wherein R^1 is hydrogen, halogen, $(C_1$-$C_6)$alkyl, halo$(C_1$-$C_4)$alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$cycloalkyl$(C_1$-$C_4)$alkyl, phenyl, or phenyl$(C_1$-$C_2)$alkyl.

4. The compound or pharmaceutically acceptable salt according to claim **1**, wherein R^1 is $(C_1$-$C_4)$alkyl.

5. The compound or pharmaceutically acceptable salt according to claim **1**, wherein R^2 is $(C_3$-$C_6)$alkoxy, $(C_3$-$C_6)$cycloalkyloxy-, heterocycloalkyloxy-, heterocycloalkyl, —$NH((C_3$-$C_6)$cycloalkyl), —$N((C_1$-$C_3)$alkyl$)((C_3$-$C_6)$cycloalkyl), —NH(heterocycloalkyl), or —$N((C_1$-$C_3)$alkyl)(heterocycloalkyl), wherein any said $(C_3$-$C_6)$alkoxy, $(C_3$-$C_6)$cycloalkyloxy-, heterocycloalkyloxy-, heterocycloalkyl, or $(C_3$-$C_6)$cycloalkyl is optionally substituted 1 or 2 times, independently, by halogen, hydroxyl, $(C_1$-$C_3)$alkoxy, amino, —$NH(C_1$-$C_3)$alkyl, —$N((C_1$-$C_3)$alkyl$)_2$, $(C_1$-$C_3)$alkyl, $(C_1$-$C_3)$alkoxy$(C_1$-$C_3)$alkyl-, amino$(C_1$-$C_3)$alkyl-, $((C_1$-$C_3)$alkyl)$NH(C_1$-$C_3)$alkyl-, $((C_1$-$C_3)$alkyl$)_2N(C_1$-$C_3)$alkyl-, $(C_3$-$C_8)$cycloalkyl, cyano, —CO_2R^a, —$C(O)NR^aR^b$, —$SO_2NR^aR^b$, phenyl, or heteroaryl.

6. The compound or pharmaceutically acceptable salt according to claim **1**, wherein R^2 is $(C_3$-$C_6)$alkoxy, $(C_3$-$C_8)$cycloalkyloxy-, or heterocycloalkyloxy-, each of which is optionally substituted by hydroxyl, $(C_1$-$C_3)$alkoxy, amino, —$NH(C_1$-$C_3)$alkyl, —$N((C_1$-$C_3)$alkyl$)_2$, $(C_1$-$C_3)$alkyl, —CO_2R^a, —$C(O)NR^aR^b$, —$SO_2NR^aR^b$, phenyl, or heteroaryl.

7. The compound or pharmaceutically acceptable salt according to claim **1**, wherein R^2 is cyclopentyloxy, cyclohexyloxy, pyrrolidinyloxy, piperidinyloxy, and tetrahydropyranyloxy, each of which is optionally substituted by hydroxyl, $(C_1$-$C_3)$alkoxy, amino, —$NH(C_1$-$C_3)$alkyl, —$N((C_1$-$C_3)$alkyl$)_2$, $(C_1$-$C_3)$alkyl, —CO_2R^a, —$C(O)NR^aR^b$, —$SO_2NR^aR^b$, phenyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrazinyl, or pyrimidinyl, wherein R^a is $(C_1$-$C_4)$alkyl or phenyl$(C_1$-$C_2)$alkyl and R^b is hydrogen or $(C_1$-$C_4)$alkyl.

8. The compound or pharmaceutically acceptable salt according to claim **1**, wherein R^2 is $(C_1$-$C_4)$alkoxy, cyclohexyloxy, or —NR^aR^b, wherein said cyclohexyloxy is optionally substituted by amino, —$NH(C_1$-$C_3)$alkyl, or —$N((C_1$-$C_3)$alkyl$)_2$.

9. The compound or pharmaceutically acceptable salt according to claim **1**, wherein R^2 is —NR^aR^b.

10. The compound or pharmaceutically acceptable salt according to claim **9**, wherein R^a is hydrogen, methyl, ethyl, cyclohexyl, tetrahydropyranyl, or piperidinyl, wherein said cyclohexyl is optionally substituted 1 or 2 times, independently, by fluorine, amino, dimethylamino, diethylamino, or morpholinyl, and wherein said piperidinyl is optionally substituted by methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 2-hydroxyethyl, 1,3-dihydroxypropan-2-yl, cyclopropylmethyl, (1-methyl-1H-pyrazol-3-yl)methyl, (6-methylpyridin-2-yl)methyl, 1-ethoxy-2-methyl-1-oxopropan-2-yl, or methylsulfonyl; and R^b is hydrogen, methyl, or ethyl.